News
Justin Schleede reaches onto a black lab bench to pick up a tray of small plastic tubes.
"These are saliva...
"If proven to be safe, we believe preventive gene editing could be one of the most important health technologies of...
Separate teams of scientists on two continents revealed Tuesday that they have created stem cells from human skin cells -...
New source of stem cells and statements by Wilmut weaken argument for use of cloning techniques, women's eggs
Today's announcement by researchers that they can create powerful stem cells from ordinary human body cells shifts both the scientific terrain and the contentious political debate, said the Center for Genetics and Society, a public interest organization.
The new stem cell technique has been called "direct reprogramming," and the cells it produces are termed "induced pluripotent stem" (iPS) cells.
"This is like an earthquake for both the science and politics of stem cell research," said CGS policy analyst Jesse Reynolds.
The prospect of producing pluripotent stem cells without either eggs or embryos signals a new chapter in the politics of stem cell research, said the Center, which supports embryonic stem cell research but has long argued that cloning-based techniques pose novel risks. Direct reprogramming promises to produce disease-specific stem cells for use in screening drugs and studying disease mechanisms, and patient-specific stem cells that researchers may learn to use for treatments and therapies - without relying on cloning and without requiring eggs from women.
Prof. Ian Wilmut, a world leader in cloning-based stem cell research, announced on Friday that he is abandoning such work due to these recent developments in induced pluripotent stem cells.
"If these results are as promising as they appear to be, they significantly undermine the case for cloning-based stem cell research," said Reynolds. "Wilmut's change of heart is significant. He holds one of two licenses in the UK to work on cloning techniques."
The new stem cell technique will impact the political landscape. "If these findings hold up, they could disconnect the stem cell debate from culture-war battles over embryo politics and abortion rights, and put an end to the use of embryonic stem cell research as a political wedge issue," said CGS Associate Executive Director Marcy Darnovsky. "Hopefully this will enable policy makers to move forward with much-needed oversight of emerging technologies, such as a federal ban on human reproductive cloning."
"The polarized and contentious debate about stem cell research demonstrates the wrong way to bring social values into discussions of powerful new technologies," Darnovsky continued. "Partisan political expediency doesn't belong in science. But we do need thoughtful debate and careful decisions about new human biotechnologies, based on their likely social consequences, and on our commitments to human rights, social justice, and the public interest."
The Center for Genetics and Society is a nonprofit information and public affairs organization working to encourage responsible uses and effective societal governance of the new human genetic and reproductive technologies.
Contact:
Jesse Reynolds
510-625-0819 ext 308
The scientist who created Dolly the sheep, a breakthrough that provoked headlines around the world a decade ago, is to...
The revolution in human genomics, though barely understood by professionals, is about to hit the street, at least for those...
Legislation is needed to prohibit reproductive cloning and reduce risks to women who provide eggs
Oakland, CA – The apparent monkey cloning success at the Oregon National Primate Research Center gives new urgency to important social and safety issues raised by cloning-based stem cell research using human tissues, said the Center for Genetics and Society, a public interest organization.
CGS and other advocates for responsible oversight of human biotechnologies focus on three concerns about research cloning (also known as somatic cell nuclear transfer): the health risks to women of extracting the hundreds of eggs that cloning research requires; the need for effective and enforceable oversight to prevent unauthorized reproductive cloning efforts; and the potential for exacerbating health disparities.
The new cloning developments highlight the need for legislation at the federal level to reduce the risks to women who provide eggs for research and to prohibit reproductive cloning. They also underscore the importance of avoiding exaggerated claims about the likelihood or imminence of cloning-based medical treatments or cures.
“The California law on eggs for research that was passed last year – the first of its kind in the U.S. – is a good place to start,” said Marcy Darnovsky, CGS Associate Executive Director. The law, SB 1260, was authored by Senator Deborah Ortiz (D-Sacramento), a champion of women's health and an early supporter of stem cell research in California. The Center for Genetics and Society, along with Planned Parenthood Affiliates of California and the Pro-Choice Alliance for Responsible Research, worked closely with the former Senator's office on the landmark bill.
Concerns about the health risks of egg extraction focus on the drugs used to "shut down" women's ovaries and those used to "hyperstimulate" the ovaries to produce multiple eggs. Both are associated with serious adverse reactions, in some cases life-threatening. Deaths have been reported. The Oregon researchers used more than 300 monkey eggs to produce one viable stem cell line. In more than a decade of cloning research, the efficiency has not improved.
Scores of countries and about a dozen U.S. states have adopted prohibitions on reproductive cloning. “But we still don't have laws against reproductive cloning either nationally or in the majority of U.S. states,” pointed out CGS policy analyst Jesse Reynolds.
Commenting on the prospect of "individually tailored" treatments derived from cloning-based stem cell lines, Darnovsky said, “The personal-repair-kit approach to stem cell research is far-fetched. To the extent that researchers and their advocates still claim that cloning techniques will lead to personalized stem cell treatments, they should recognize that – even if these are someday technically possible – they would be enormously expensive, and thus would likely worsen our already shameful health disparities. We need to prioritize stem cell research mostly likely to produce treatments that can be made widely available.”
Contact:
Marcy Darnovsky
510-625-0819 x305
Although not a transcript, this is an accurate record of what I said on November 14, 2007 at a Congressional...



